1. Home
  2. OXSQ vs ENGN Comparison

OXSQ vs ENGN Comparison

Compare OXSQ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oxford Square Capital Corp.

OXSQ

Oxford Square Capital Corp.

N/A

Current Price

$0.77

Market Cap

135.7M

Sector

Finance

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$2.37

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
OXSQ
ENGN
Founded
2003
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
135.7M
117.2M
IPO Year
2003
2023

Fundamental Metrics

Financial Performance
Metric
OXSQ
ENGN
Price
$0.77
$2.37
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $3.86
AVG Volume (30 Days)
★ 1.9M
1.4M
Earning Date
10-30-2026
12-21-2026
Dividend Yield
★ 22.59%
N/A
EPS Growth
N/A
★ 56.85
EPS
★ 0.14
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.59
N/A
P/E Ratio
$5.67
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$1.40
52 Week High
$1.98
$12.25

Technical Indicators

Market Signals
Indicator
OXSQ
ENGN
Relative Strength Index (RSI) 18.84 74.35
Support Level N/A $1.70
Resistance Level $1.58 $8.93
Average True Range (ATR) 0.07 0.16
MACD -0.02 0.08
Stochastic Oscillator 1.97 86.32

Price Performance

Historical Comparison
OXSQ
ENGN

About OXSQ Oxford Square Capital Corp.

Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: